Zhejiang Xinguang Pharmaceutical 新光药业
2 significant filings since 29 May 2026: 2 on major holder selling. The latest, on 3 Sep 2026: 关于公司持股5%以上股东股份减持计划届满的公告.
自 29 May 2026 起有 2 份重大公告：major holder selling 2 份。最新一份（3 Sep 2026）：关于公司持股5%以上股东股份减持计划届满的公告。
As of 25 Sep 2026 截至2026年9月25日
Zhejiang Xinguang Pharmaceutical 新光药业, listed in 2016, operates in the Traditional Chinese Medicine industry. The company reported revenue of RMB265.4m in 2025, down 0.9% from RMB267.7m in 2024. Attributable net profit rose to RMB54.2m from RMB50.4m, up 7.6%. Net profit excluding non-recurring items increased by 9.2%. Basic EPS was RMB0.34, up from RMB0.31. Operating cash flow per share was RMB0.43, ahead of net profit with a ratio of 1.27x. As of 30 Jun 2026, liabilities to assets stood at 6.1%, with a current ratio of 16.76 and quick ratio of 16.13. Receivable days were 14 and inventory days 85. In the first half of 2026, revenue was RMB142.6m, up 1.2%, and attributable net profit was RMB39.7m, up 24.5%. The actual controller and largest holder is 王岳钧, holding 38.25%.
新光药业于2016年上市，属于中药行业。2025年营业收入2.65亿元，较2024年2.68亿元下降0.9%；归母净利润5,421.1万元，较5,039.0万元上升7.6%；扣非后净利润同比上升9.2%。基本每股收益0.34元，较0.31元上升。每股经营现金流0.43元，经营现金流与净利润之比为1.27倍。截至2026年6月30日，资产负债率6.1%，流动比率16.76，速动比率16.13，应收账款周转天数14，存货周转天数85。2026年上半年营业收入1.43亿元，同比上升1.2%；归母净利润3,971.2万元，同比上升24.5%。实际控制人及第一大股东为王岳钧，持股38.25%。
- Revenue in the full year 2026
2026全年营业收入 - Attributable net profit in the full year 2026
2026全年归属于母公司股东的净利润 - Operating cash flow to net profit ratio in 2026
2026年经营现金流与净利润之比 - Liabilities to assets ratio at 31 Dec 2026
2026年12月30日资产负债率 - Shareholding percentage of 王岳钧 as of 31 Dec 2026
截至2026年12月30日王岳钧的持股比例 - Next distribution announcement
下一次分红公告
- Company: Zhejiang Xinguang Pharmaceutical 新光药业, Shenzhen Stock Exchange 300519; industry Traditional Chinese Medicine; listed 24 Jun 2016.
公司：新光药业，深圳证券交易所 300519；行业：中药；上市日期：2016年6月24日。 - Close on 24 Sep 2026 RMB14.56; close on 24 Sep 2025 RMB15.68, RMB15.35 in today's terms; one-year change, adjusted for distributions and share changes -5.1%.
2026年9月24日收盘价14.56元；2025年9月24日收盘价15.68元（前复权15.35元）；一年涨跌幅（复权）-5.1%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB11.85 to RMB17.19.
52周区间（前复权）11.85元至17.19元。 - Market capitalisation RMB2.33bn; P/E TTM 37.6; price to book 2.81x.
总市值23.30亿元；市盈率（TTM）37.6；市净率2.81倍。 - Revenue 2025 RMB265.4m; 2024 RMB267.7m; change -0.9%.
营业收入2025年2.65亿元；2024年2.68亿元；同比-0.9%。 - Attributable net profit 2025 RMB54.2m; 2024 RMB50.4m; change +7.6%.
归属于母公司股东的净利润2025年5,421.1万元；2024年5,039.0万元；同比+7.6%。 - Net profit excluding non-recurring items, 2025 change +9.2%.
2025年扣除非经常性损益后的净利润同比+9.2%。 - Basic EPS 2025 RMB0.34; 2024 RMB0.31.
基本每股收益2025年0.34元；2024年0.31元。 - Operating cash flow per share 2025 RMB0.43; 2024 RMB0.33; operating cash flow to net profit 1.27x.
每股经营现金流2025年0.43元；2024年0.33元；经营现金流与净利润之比1.27倍。 - 2025 gross margin 38.8%; net margin 20.4%; ROE 6.5%.
2025年毛利率38.8%；净利率20.4%；净资产收益率6.5%。 - At 30 Jun 2026: liabilities to assets 6.1%; current ratio 16.76; quick ratio 16.13; receivable days 14; inventory days 85.
截至2026年6月30日：资产负债率6.1%；流动比率16.76；速动比率16.13；应收账款周转天数14；存货周转天数85。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB142.6m, change +1.2%; attributable net profit RMB39.7m, change +24.5%; operating cash flow per share RMB0.36.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入1.43亿元，同比+1.2%；归母净利润3,971.2万元，同比+24.5%；每股经营现金流0.36元。 - Ownership: actual controller 王岳钧; largest holder at 30 Jun 2026: 王岳钧, 38.25%.
股权：实际控制人：王岳钧；2026年6月30日第一大股东：王岳钧，持股38.25%。 - Latest distribution: ex-date 29 May 2026, cash RMB0.30 per share.
最近一次分配：除权除息日2026年5月29日，每股现金0.30元。 - Aurelian Grade B, score 78.7 of 100, graded within a peer group of 66 companies in its industry; no rank among peers is given.
金源评级B，得分78.7（满分100），于行业同业66家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。